Form 4: Altimmune Director Teri Lawver Receives Stock Option Grant
Director Compensation Disclosure
Director Teri Lawver was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.
Summary
- Director Teri Lawver received a grant of 48,800 stock options on May 1, 2026.
- The options have an exercise price of $2.82 per share.
- The options are set to expire on May 1, 2036.
- The grant is part of the standard non-employee director compensation policy.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial position.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $2.82 exercise price.
Future Outlook
The options vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent upon continued service.
Management Comments
- The options were granted pursuant to the Company's non-employee director compensation policy.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The use of monthly vesting over one year is a standard retention mechanism for board members in small-cap biotech firms.
- The grant size is consistent with typical compensation packages for directors in companies of similar market capitalization.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation | Grant of equity to a non-employee director. | 05/01/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minor dilution impact for shareholders upon future exercise of options.
Next Steps
- Vesting of options in monthly installments over the next 12 months.
Key Dates
| Date | Description |
|---|---|
| 05/01/2026 | Transaction date of the stock option grant. |
| 05/01/2036 | Expiration date of the granted stock options. |
Keywords
Altimmune, ALT, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.